Praveen Nair
Vice President of Translational Pharmacology Immuneering Corp.
Seminars
Tuesday 8th September 2026
Deep Cyclic Inhibition of MEK in RAS-Mutant Tumors: Constraining MAPK-Axis Escape and Preserving Combination Optionality
3:00 pm
- The emerging resistance landscape for chronic RAS inhibition, including recurrent MAPK-axis reactivation mechanisms
- The rationale for deep cyclic MEK inhibition as an alternative evolutionary pressure model
- Clinical ctDNA evidence from atebimetinib-treated RAS-mutant tumors, including PDAC
- How this profile may support combination strategies with mutant-selective RAS inhibitors, RAF inhibitors, chemotherapy, immunotherapy, RTK-directed agents, or radiotherapy
